Aldeyra Therapeutics, Inc. financial data

Symbol
ALDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
131 Hartwell Avenue, Suite 320, Lexington, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Aldexa Therapeutics, Inc. (to 3/4/2014), Neuron Systems Inc (to 8/1/2008)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 603 % -38.2%
Debt-to-equity 23.9 % +20.9%
Return On Equity -33.8 %
Return On Assets -26.9 % +10.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.4M shares +1.41%
Common Stock, Shares, Outstanding 59.4M shares +1.04%
Entity Public Float 483M USD +112%
Common Stock, Value, Issued 59.4K USD +1.04%
Weighted Average Number of Shares Outstanding, Basic 59.4M shares +1.06%
Weighted Average Number of Shares Outstanding, Diluted 59.4M shares +1.06%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.4M USD -16.2%
General and Administrative Expense 10.6M USD -37.2%
Operating Income (Loss) -43M USD +22.6%
Nonoperating Income (Expense) 5.18M USD +45.1%
Net Income (Loss) Attributable to Parent -37.9M USD +27.3%
Earnings Per Share, Basic -0.64 USD/shares +28.1%
Earnings Per Share, Diluted -0.64 USD/shares +28.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71M USD
Marketable Securities, Current 49.3M USD
Other Assets, Current 0 USD -100%
Assets, Current 126M USD -19.2%
Property, Plant and Equipment, Net 2.72K USD -72.2%
Operating Lease, Right-of-Use Asset 392K USD +207%
Assets 126M USD -19%
Accounts Payable, Current 254K USD -6.05%
Employee-related Liabilities, Current 2.57M USD -55.7%
Accrued Liabilities, Current 5.84M USD -37.2%
Liabilities, Current 27.6M USD +76.8%
Operating Lease, Liability, Noncurrent 139K USD
Liabilities 27.7M USD +7.77%
Accumulated Other Comprehensive Income (Loss), Net of Tax -9.66K USD
Retained Earnings (Accumulated Deficit) -419M USD -9.93%
Stockholders' Equity Attributable to Parent 98.3M USD -24.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 123M USD
Liabilities and Equity 126M USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.97M USD -5.6%
Net Cash Provided by (Used in) Financing Activities 18.2K USD -65.4%
Net Cash Provided by (Used in) Investing Activities -30.4M USD -201%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 59.4M shares +1.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -40.3M USD -296%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 71M USD -53.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 440K USD +10.7%
Deferred Tax Assets, Valuation Allowance 105M USD +10.8%
Deferred Tax Assets, Gross 105M USD +10.9%
Operating Lease, Liability 394K USD +204%
Depreciation 60.6K USD -9.47%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.9M USD +26.8%
Lessee, Operating Lease, Liability, to be Paid 423K USD +218%
Operating Lease, Liability, Current 255K USD +96.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 285K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 138K USD +3.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.2K USD +742%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 140K USD +105%
Share-based Payment Arrangement, Expense 3.47M USD -67.9%
Interest Expense 2.03M USD +7.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%